Vashistha, Ritwik
Noor, Zubdahe
Dasgupta, Shibasish
Pu, Jie
Deng, Shibing
Clinical trials referenced in this document:
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
https://doi.org/10.1200/jco.2023.41.16_suppl.4515
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
https://doi.org/10.1136/jitc-2020-001246
665 JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma
https://doi.org/10.1136/jitc-2022-sitc2022.0665
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
https://doi.org/10.1007/s10147-021-02067-8
Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial.
https://doi.org/10.1200/jco.2024.42.4_suppl.581
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
https://doi.org/10.1200/jco.2023.41.16_suppl.4516
Application of statistical machine learning in biomarker selection
https://doi.org/10.1038/s41598-023-45323-9
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
https://doi.org/10.1200/jco.22.01792
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
https://doi.org/10.1200/jco.2023.41.6_suppl.508
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).
https://doi.org/10.1200/jco.2024.42.4_suppl.600
Article History
Received: 8 March 2023
Accepted: 18 October 2023
First Online: 26 October 2023
Change Date: 25 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-52345-4
Competing interests
: RV was a paid intern to Pfizer Healthcare India Private Limited, Chennai in connection with the development of this manuscript. SD, JP, and SD are Pfizer employees with Pfizer stock ownership. ZN is a Pfizer employee.